Gene Therapy Market

7500+ companies worldwide approach us every year for their revenue growth initiatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Gene Therapy Market Size, Growth by Vectors (Non-viral (Oligonucleotides), Viral (Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecasts to 2027

FREE BROCHURE FREE SAMPLE REPORT

Report Code: BT 7506 Jul, 2022, by marketsandmarkets.com

The global Gene Therapy Market in terms of revenue was estimated to be worth $7.3 billion in 2022 and is poised to reach $17.2 billion by 2027, growing at a CAGR of 18.6% from 2022 to 2027. Factors such as growing approvals of gene therapy products and rising investment in research and development of gene therapies are driving the market's growth. However, the high cost of gene therapy is restraining the growth of this market.

Gene Therapy Market

To know about the assumptions considered for the study, Request for Free Sample Report

Gene Therapy Market Dynamics

Drivers: Funding for gene therapy research

Gene therapy is one of the latest treatment methods in the healthcare industry. It has shown promising results in treating cancer and other genetic diseases. As a result, the focus on gene therapy research has increased over the last few years. In addition, many companies focus on growth opportunities in this market by launching new and advanced products. For example:

In March 2022, the National Heart Lung and Blood Institute granted USD 12 million to an Indiana University School of Medicine researcher. The grant is for exploring major themes in a gene therapy approach to safer and potentially curative treatments for hemophilia.
In May 2019, Locana, Inc., a leading RNA-targeting gene therapy company, received USD 55 million in Series A financing led by ARCH Venture Partners, with participation from Temasek and Lightstone Ventures (all existing investors). The company will utilize this fund for its RNA-targeting gene therapy pipeline programs.

Opportunities: Strong product pipeline

Gene therapy is a promising revenue-generation area for pharmaceutical & biotechnology companies. Currently, most key players are focusing on new gene therapy products to capitalize the gene therapy market growth opportunities. Some of these products are in the pre-clinical stage, while others are in the clinical phase and are expected to secure approval in the coming years. In addition, companies operating in the gene therapy industry are focusing on various disease areas, including hemophilia A & B, Fabry disease, wet age-related macular degeneration, mucopolysaccharidosis type II, ornithine transcarbamylase (OTC) deficiency, achromatopsia, and multiple myeloma. As a result, the patient pool for gene therapies is expected to increase in the coming years.

Challenges: High treatment cost

Currently, the cost of gene therapies is very high and can reach up to USD 1 million for one patient, depending on the disease condition. Most gene therapy products in the US and EU are covered under reimbursement programs. However, it is difficult for people not covered by insurance to afford such high-cost treatments.

The non-viral vectors segment dominated the gene therapy market in 2021

On the basis of vectors, the gene therapy industry is segmented into non-viral vectors and viral vectors. Non-viral vectors accounted for the largest market share in 2021. Factors such as the lower immunogenicity of non-viral vectors in comparison to viral vectors, coupled with the easier mass production of non-viral vectors, are driving the growth of this segment.

Gene Therapy Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for Gene therapy market report in 2021.

North America accounted for the largest share of the global Gene therapy industry in 2021. The significant government and private investments to develop advanced gene therapy products, the high growing adoption rate of these products, and the presence of key market players in the region attribute to a large share of North America in the global market analysis.

Gene Therapy Market Key Players

Key players in the global Cell and gene therapy market include Biogen (US), Sarepta Therapeutics (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Novartis AG (Switzerland), Orchard Therapeutics Plc (UK), Spark Therapeutics, Inc. (A Part Of ýF. Hoffmann-La Roche) (US), AGC Biologics (US), Anges, Inc. (Japan), Bluebird Bio, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Dynavax Technologies (US), Human Stem Cells Institute (Russia), Sibiono Genetech Co., Ltd. (China), Shanghai Sunway Biotech Co., Ltd. (China), Uniqure N.V. (Netherland), Gensight Biologics S.A. (France), Celgene Corporation (A Bristol-Myers Squibb Company) (US), Cellectis (France), Sangamo Therapeutics (US), Mustang Bio (US), AGTC (Applied Genetic Technologies Corporation) (US), and Poseida Therapeutics, Inc. (US).

Gene Therapy Market Report Scope

Report Metric	Details
Market Revenue in 2022	$7.3 billion
Estimated Value by 2027	$17.2 billion
Growth Rate	poised to grow at a CAGR of 18.6%
Largest Share Segments	By Vectors - the Gene therapy industry is segmented into non-viral vectors and viral vectors. By Challenges - Currently, the cost of gene therapies is very high, and it can reach up to USD 1 million for one patient depending on the disease condition.
Market Report Segmentation	Vectors, Indication, Delivery Method, End User & Region
Growth Drivers	High incidence of cancer and other target diseases Product approvals Funding for gene therapy research
Growth Opportunities	Strong product pipeline
Geographies covered	North America, Europe, APAC, MEA, and Latin America

This report categorizes the global gene therapy market into the following segments and subsegments:

By Vectors

Non-viral Vectors
- Oligonucleotides
- Other Non-viral Vectors
Viral Vectors
- Retro Viral Vectors
- Adeno-associated Virus Vectors
- Other Viral Vectors

By Indication

Neurological Diseases
Cancer
DMD (Duchenne Muscular Dystrophy)
Hepatological Diseases
Other Indications

By Delivery Method

In Vivo
Ex Vivo

By Region

North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
Asia Pacific (APAC)
- China
- Japan
- Rest of Asia Pacific (RoAPAC)
Rest of the World (RoW)

Recent Developments

In February 2022, Sarepta Therpeutics (US) announced a collaboration to use GenEdit’s NanoGalaxy platform and Sarepta’s gene editing technology to develop gene editing therapeutics to treat neuromuscular diseases.
In May 2022, Novartis AG (Switzerland) received FDA approval for KYMRIAH for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Frequently Asked Questions (FAQ):

What is the size of Gene Therapy Market ?

The Gene Therapy Market size is projected to reach USD 17.2 Billion by 2027, growing at a CAGR of 18.6%.

Why is Gene Therapy Market Growing?

Factors such as growing cases of cancer and neurological diseases, rising gene therapy product approvals, and increasing investment in research and development of gene therapies will drive the market growth. However, factors such as high cost associated with gene therapy are restraining the growth of this market.

Who all are the prominent players of Gene Therapy Market ?

Key players in the gene therapy market include Biogen (US), Novartis AG (Switzerland), Gilead Sciences Inc. (US), and Sarepta Therapeutics (US)

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 23)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE
           1.3.1 MARKETS COVERED
    1.4 YEARS CONSIDERED
    1.5 CURRENCY CONSIDERED
    1.6 LIMITATIONS
    1.7 STAKEHOLDERS
    1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 26)
    2.1 RESEARCH DATA
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    FIGURE 2 KEY DATA FROM SECONDARY SOURCES
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
           2.2.2 COMPANY REVENUE ANALYSIS
                    FIGURE 4 COMPANY REVENUE ANALYSIS
           2.2.3 GROWTH FORECAST
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
          FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. - 32)
    FIGURE 6 GENE THERAPY MARKET, BY VECTOR, 2022 VS. 2027 (USD MILLION)
    FIGURE 7 GLOBAL MARKET, BY DELIVERY METHOD, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 GLOBAL MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 GLOBAL MARKET: REGIONAL SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 35)
    4.1 GLOBAL MARKET OVERVIEW
          FIGURE 10 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET, BY VECTOR (2021)
          FIGURE 11 NON-VIRAL VECTORS DOMINATE NORTH AMERICAN GENE GLOBAL MARKET
    4.3 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
          FIGURE 12 APAC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 37)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 13 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High incidence of cancer and other target diseases
                                TABLE 1 NUMBER OF NEW CANCER CASES, 2020 VS. 2025
                    5.2.1.2 Product approvals
                                TABLE 2 PRODUCT APPROVALS, 2015–2021
                    5.2.1.3 Funding for gene therapy research
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Strong product pipeline
                                TABLE 3 GLOBAL MARKET: INDICATIVE LIST OF PIPELINE DRUGS
           5.2.3 CHALLENGES
                    5.2.3.1 High treatment costs
                                TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2021
    5.3 PRICING ANALYSIS
    5.4 TECHNOLOGY ANALYSIS
          FIGURE 14 KEY STEPS IN GENE THERAPY
    5.5 SUPPLY CHAIN ANALYSIS
           5.5.1 PROMINENT COMPANIES
           5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES (SMES)
           5.5.3 END USERS
                    FIGURE 15 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS OF GLOBAL MARKET
          TABLE 5 STAKEHOLDERS IN THE GENE THERAPY ECOSYSTEM AND THEIR ROLES
    5.7 KEY CONFERENCES AND EVENTS IN 2022–2023
          TABLE 6 GLOBAL MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.8 REGULATORY ANALYSIS
          TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.9 PORTER’S FIVE FORCES ANALYSIS
          TABLE 11 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF SUPPLIERS
           5.9.4 BARGAINING POWER OF BUYERS
           5.9.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
    5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GENE THERAPY PRODUCTS
           5.10.2 BUYING CRITERIA FOR GENE THERAPY PRODUCTS
                     FIGURE 17 KEY BUYING CRITERIA FOR END USERS

6 GENE THERAPY MARKET, BY VECTOR (Page No. - 49)
    6.1 INTRODUCTION
          TABLE 12 GLOBAL MARKET, BY VECTOR, 2020–2027 (USD MILLION)
    6.2 NON-VIRAL VECTORS
          TABLE 13 GLOBAL MARKET FOR NON-VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 14 GLOBAL MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
           6.2.1 OLIGONUCLEOTIDES
                    6.2.1.1 Oligonucleotides account for the largest share of the non-viral vectors market
                                TABLE 15 GLOBAL MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
           6.2.2 OTHER NON-VIRAL VECTORS
                    TABLE 16 GLOBAL MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
    6.3 VIRAL VECTORS
          TABLE 17 GLOBAL MARKET FOR VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 18 GLOBAL MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
           6.3.1 RETROVIRAL VECTORS
                    TABLE 19 GLOBAL MARKET FOR RETROVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 20 GLOBAL MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                    6.3.1.1 Gamma-retroviral vectors
                               6.3.1.1.1 Availability of wide range of gamma-retroviral vectors supports market growth
                                              TABLE 21 GLOBAL MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
                    6.3.1.2 Lentiviral vectors
                               6.3.1.2.1 North America to dominate lentiviral vectors market
                                              TABLE 22 GLOBAL MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
           6.3.2 ADENO-ASSOCIATED VIRUS VECTORS
                    6.3.2.1 Potential applications in in vivo applications to drive interest in AAV vectors
                                TABLE 23 GLOBAL MARKET FOR AAV VECTORS, BY REGION, 2020–2027 (USD MILLION)
           6.3.3 OTHER VIRAL VECTORS
                    TABLE 24 MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)

7 GENE THERAPY MARKET, BY INDICATION (Page No. - 56)
    7.1 INTRODUCTION
          TABLE 25 GLOBAL MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    7.2 NEUROLOGICAL DISEASES
           7.2.1 NEUROLOGICAL DISEASES TO FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
                    TABLE 26 GLOBAL MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2020–2027 (USD MILLION)
    7.3 CANCER
           7.3.1 GROWING DEMAND FOR CANCER THERAPIES TO DRIVE MARKET GROWTH
                    TABLE 27 NUMBER OF NEW CANCER CASES, BY TYPE, 2020–2040
                    TABLE 28 GLOBAL MARKET FOR CANCER, BY REGION, 2020–2027 (USD MILLION)
    7.4 DUCHENNE MUSCULAR DYSTROPHY
           7.4.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
                    TABLE 29 GLOBAL MARKET FOR DMD, BY REGION, 2020–2027 (USD MILLION)
    7.5 HEPATOLOGICAL DISEASES
           7.5.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS TO SUPPORT MARKET GROWTH
                    TABLE 30 GLOBAL MARKET FOR HEPATOLOGICAL DISEASES, BY REGION, 2020–2027 (USD MILLION)
    7.6 OTHER INDICATIONS
          TABLE 31 GLOBAL MARKET FOR OTHER INDICATIONS, BY REGION, 2020–2027 (USD MILLION)

8 GENE THERAPY MARKET, BY DELIVERY METHOD (Page No. - 62)
    8.1 INTRODUCTION
          TABLE 32 GLOBAL MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
    8.2 IN VIVO GENE THERAPY
           8.2.1 IN VIVO GENE THERAPY TO DOMINATE MARKET
                    TABLE 33 IN VIVO GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.3 EX VIVO GENE THERAPY
           8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGH GROWTH
                    TABLE 34 EX VIVO GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)

9 GENE THERAPY MARKET, BY REGION (Page No. - 65)
    9.1 INTRODUCTION
          TABLE 35 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA
          FIGURE 18 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
          TABLE 36 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 37 NORTH AMERICA: MARKET, BY VECTOR, 2020–2027 (USD MILLION)
          TABLE 38 NORTH AMERICA: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 39 NORTH AMERICA: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 40 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 41 NORTH AMERICA: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
          TABLE 42 NORTH AMERICA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US dominates the global gene therapy market
                                TABLE 43 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
                                TABLE 44 US FDA GENE THERAPY PRODUCT APPROVALS
                                TABLE 45 US: MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 46 US: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 47 US: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 48 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 49 US: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 50 US: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Growing burden of cancer supports market growth in Canada
                                TABLE 51 CANADA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 52 CANADA: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 53 CANADA: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 54 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 55 CANADA: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 56 CANADA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    9.3 EUROPE
           TABLE 57 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 58 EUROPE: MARKET, BY VECTOR, 2020–2027 (USD MILLION)
           TABLE 59 EUROPE: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 60 EUROPE: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 61 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 62 EUROPE: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
           TABLE 63 EUROPE: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany dominates European gene therapy market
                                TABLE 64 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 65 GERMANY: MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 66 GERMANY: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 67 GERMANY: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 68 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 69 GERMANY: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 70 GERMANY: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Increasing cancer incidence to support market growth
                                TABLE 71 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 72 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 73 FRANCE: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 74 FRANCE: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 75 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 76 FRANCE: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 77 FRANCE: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Rising incidence of melanoma to support market growth in UK
                                TABLE 78 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 79 UK: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 80 UK: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 81 UK: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 82 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 83 UK: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 84 UK: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 High incidence of targeted diseases and increasing healthcare spending to drive Italian market growth
                                TABLE 85 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 86 ITALY: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 87 ITALY: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 88 ITALY: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 89 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 90 ITALY: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 91 ITALY: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain
                                TABLE 92 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 93 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 94 SPAIN: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 95 SPAIN: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 96 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 97 SPAIN: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 98 SPAIN: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 99 ROE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                    TABLE 100 ROE: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 101 ROE: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 102 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 103 ROE: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                    TABLE 104 ROE: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC
          FIGURE 19 ASIA PACIFIC: GENE THERAPY MARKET SNAPSHOT
                              TABLE 105 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 106 ASIA PACIFIC: MARKET, BY VECTOR, 2020–2027 (USD MILLION)
          TABLE 107 ASIA PACIFIC: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 108 ASIA PACIFIC: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 109 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 110 ASIA PACIFIC: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
          TABLE 111 ASIA PACIFIC: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Japan dominates the APAC gene therapy market
                                TABLE 112 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 113 JAPAN: MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 114 JAPAN: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 115 JAPAN: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 116 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 117 JAPAN: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 118 JAPAN: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China
                                TABLE 119 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                TABLE 120 CHINA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                TABLE 121 CHINA: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 122 CHINA: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 123 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 124 CHINA: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                                TABLE 125 CHINA: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
           9.4.3 REST OF ASIA PACIFIC
                    TABLE 126 ROAPAC: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                    TABLE 127 ROAPAC: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 128 ROAPAC: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 129 ROAPAC: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 130 ROAPAC: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
                    TABLE 131 ROAPAC: MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    9.5 REST OF THE WORLD
          TABLE 132 ROW: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
          TABLE 133 ROW: MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 134 ROW: MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
          TABLE 135 ROW: MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 136 ROW: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 137 ROW: MARKET, BY INDICATION, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 102)
     10.1 OVERVIEW
             FIGURE 20 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
     10.2 MARKET SHARE ANALYSIS, 2021
             FIGURE 21 GLOBAL MARKET SHARE ANALYSIS, 2021
             TABLE 138 GLOBAL MARKET: DEGREE OF COMPETITION
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 22 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GENE THERAPY, 2019–2021
     10.4 COMPANY EVALUATION QUADRANT
             10.4.1 STARS
             10.4.2 EMERGING LEADERS
             10.4.3 PERVASIVE PLAYERS
             10.4.4 PARTICIPANTS
                        FIGURE 23 GLOBAL MARKET: COMPANY EVALUATION QUADRANT, 2021
     10.5 COMPANY FOOTPRINT ANALYSIS
             10.5.1 PRODUCT FOOTPRINT OF COMPANIES
                        TABLE 139 GLOBAL MARKET: COMPANY PRODUCT FOOTPRINT (2021) ACROSS INDICATIONS
     10.6 COMPETITIVE SCENARIO
              TABLE 140 PRODUCT APPROVALS, 2018–2022
              TABLE 141 DEALS, 2018–2022
              TABLE 142 OTHER DEVELOPMENTS, 2018-2022

11 COMPANY PROFILES (Page No. - 110)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
     11.1 BIOGEN
              TABLE 143 BIOGEN: BUSINESS OVERVIEW
              FIGURE 24 BIOGEN: COMPANY SNAPSHOT
     11.2 SAREPTA THERAPEUTICS
              TABLE 144 SAREPTA THERAPEUTICS: BUSINESS OVERVIEW
              FIGURE 25 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
     11.3 GILEAD SCIENCES, INC.
              TABLE 145 GILEAD SCIENCES INC: BUSINESS OVERVIEW
              FIGURE 26 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
     11.4 AMGEN, INC.
              TABLE 146 AMGEN INC: BUSINESS OVERVIEW
              FIGURE 27 AMGEN, INC.: COMPANY SNAPSHOT
     11.5 NOVARTIS AG
              TABLE 147 NOVARTIS AG: BUSINESS OVERVIEW
              FIGURE 28 NOVARTIS AG: COMPANY SNAPSHOT
     11.6 ORCHARD THERAPEUTICS PLC
              TABLE 148 ORCHARD THERAPEUTICS PLC: BUSINESS OVERVIEW
              FIGURE 29 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT
     11.7 SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY)
              TABLE 149 SPARK THERAPEUTICS INC: BUSINESS OVERVIEW
     11.8 AGC BIOLOGICS
              TABLE 150 AGC BIOLOGICS: BUSINESS OVERVIEW
     11.9 ANGES, INC.
              TABLE 151 ANGES INC: BUSINESS OVERVIEW
              FIGURE 30 ANGES, INC.: COMPANY SNAPSHOT
     11.1 BLUEBIRD BIO, INC.
              TABLE 152 BLUEBIRD BIO: BUSINESS OVERVIEW
              FIGURE 31 BLUEBIRD BIO: COMPANY SNAPSHOT
     11.11 JAZZ PHARMACEUTICALS PLC
              TABLE 153 JAZZ PHARMACEUTICALS: BUSINESS OVERVIEW
              FIGURE 32 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT
     11.12 DYNAVAX TECHNOLOGIES
              TABLE 154 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
              FIGURE 33 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
     11.13 HUMAN STEM CELLS INSTITUTE
              TABLE 155 HUMAN STEM CELLS INSTITUTE: BUSINESS OVERVIEW
     11.14 SIBIONO GENETECH CO., LTD.
              TABLE 156 SIBIONO GENETECH CO LTD: BUSINESS OVERVIEW
     11.15 SHANGHAI SUNWAY BIOTECH CO., LTD.
              TABLE 157 SHANGHAI SUNWAY BIOTECH CO LTD: BUSINESS OVERVIEW
     11.16 UNIQURE N.V.
              TABLE 158 UNIQURE NV: BUSINESS OVERVIEW
     11.17 GENSIGHT BIOLOGICS S.A.
              TABLE 159 GENSIGHT BIOLOGICS SA: BUSINESS OVERVIEW
     11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
              TABLE 160 CELGENE CORPORATION: BUSINESS OVERVIEW
     11.19 CELLECTIS
              TABLE 161 CELLECTIS: BUSINESS OVERVIEW
     11.2 SANGAMO THERAPEUTICS
              TABLE 162 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW
     11.21 MUSTANG BIO
              TABLE 163 MUSTANG BIO: BUSINESS OVERVIEW
     11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
              TABLE 164 AGTC: BUSINESS OVERVIEW
     11.23 POSEIDA THERAPEUTICS, INC.
              TABLE 165 POSEIDA THERAPEUTICS INC: BUSINESS OVERVIEW

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 153)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATION OPTIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global gene therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study included corporate filings (such as annual reports, SEC filings, and financial statements), research journals, press releases, and trade, business, and professional associations. These secondary sources were used to identify and collect useful information for this extensive, technical, and commercial study of the gene therapy market. Secondary research was mainly used to obtain key information about the industry’s total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, market trends, and key developments by both public and private organizations in the gene therapy market.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global gene therapy market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across four major regions, namely, North America, Europe, the Asia Pacific, and Rest of the World. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Gene Therapy Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the gene therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The key players in the industry and market have been identified through extensive primary and secondary research.
The revenues generated from the gene therapy business of leading players have been determined through primary and secondary research.
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Report Objectives

To define, describe, and forecast the gene therapy market on the basis of vectors, indication, delivery method, and region
To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the overall gene therapy market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the revenue of the market segments with respect to four main regions, namely, North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, and the Rest of Asia Pacific), and Rest of the World.
To profile the key market players and comprehensively analyze their market shares and core competencies
To track and analyze competitive developments such as product launches, agreements, partnerships, acquisitions, business expansions, and research & development activities in the gene therapy market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report: